Cerus Corp
NASDAQ:CERS

  • LAST PRICE
    1.8900
  • TODAY'S CHANGE (%)
    -0.1400 (-6.8966%)
  • Bid / Lots
    1.8500/ 6
  • Ask / Lots
    1.9300/ 6
  • Open / Previous Close
    1.9800 / 2.0300
  • Day Range
    1.8600
    1.9950
  • 52 Week Range
    1.3750
    2.5850
  • Volume
    1,595,757

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Oct 30, 2024

      Show headlines and story abstract

    • 4:02PM ET on Wednesday Oct 30, 2024 by MT Newswires
      Companies Mentioned: CERS
      04:02 PM EDT, 10/30/2024 (MT Newswires) -- ...

    • 4:00PM ET on Wednesday Oct 30, 2024 by Dow Jones
      Companies Mentioned: CERS
      Operating lease liabilities -- non-current 12,270 13,751 Other non-current liabilities 3,796 3,236 ----------- ---------- Total liabilities 135,258 144,304 ----------- ---------- Stockholders' equity: 53,489 52,650 ----------- ---------- Noncontrolling interest 792 794 ----------- ---------- Total liabilities and stockholders' equity $ 189,539 $ 197,748 =========== ========== CERUS CORPORATION UNAUDITED RECONCILIATION OF NON-GAAP ADJUSTED EBITDA (in thousands) Three Months Ended Nine Months Ended September 30 September 30 ------------------ ---------------------- 2024 2023 2024 2023 -------- -------- --------- ----------- Net loss attributable to Cerus Corporation $(2,934) $(7,267) $(18,397) $(36,161) Adjustments to net loss attributable to Cerus Corporation: Net loss attributable to noncontrolling interest - (19) (2) (97) Provision for income taxes 76 78 94 253 Total non-operating expense, net (i) 1,897 1,965 5,529 4,976 ------ ------ ------- ------- Loss from operations (961) (5,243) (12,776) (31,029) Adjustments to loss from operations: Operating depreciation and amortization 1,120 1,143 3,464 3,313 Government contract revenue (ii) (4,639) (7,479) (15,109) (23,856) Direct expenses attributable to government contracts (iii) 3,038 4,991 9,513 16,800 Share-based compensation (iv) 5,830 3,979 17,363 15,368 Costs attributable to noncontrolling interest (v) - 37 3 210 Restructuring (vi) - 1,600 - 3,728 ------ ------ ------- ------- Non-GAAP adjusted EBITDA $ 4,388 $ (972) $ 2,458 $(15,466) ====== ====== ======= ======= i. Includes interest income/expense and foreign exchange gains/losses. ii. Represents revenue related to the cost reimbursement provisions under our government contracts. iii. Represents the direct expenses attributable to work supporting government contracts, which are reimbursed and reflected under government contract revenue in the condensed consolidated statement of operations. iv. Represents non-cash stock-based compensation. v. Represents costs associated with the noncontrolling interest in Cerus Zhongbaokang (Shandong) Biomedical Co., LTD. vi. Represents costs associated with the Company's restructuring plan implemented in June 2023.

    • 4:00PM ET on Wednesday Oct 30, 2024 by Dow Jones
      Companies Mentioned: CERS

  • Oct 18, 2024

Peers Headlines